Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CAR-BIG Study | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit of antidepressant therapy in real-world practice.
While there are many antidepressants from which physicians can select based on efficacy and tolerability profile, evidence on effectiveness and safety outcomes of new antidepressants in real clinical practice among Korean MDD population is limited.
Hence, this study will explore the following primary, secondary objectives using national health insurance database :
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1. Escitalopram Cohort |
| ||
| 2. Paroxetine Cohort |
| ||
| 3. Fluoxetine Cohort |
| ||
| 4. Mirtazapine Cohort |
| ||
| 5. Duloxetine Cohort |
| ||
| 6. Sertraline Cohort |
| ||
| 7. Venlafaxine Cohort |
| ||
| 8. Tianeptine Cohort |
| ||
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Escitalopram | Drug | Treatment for depression |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Medication Possession Ratio (MPR) During First 180 Days of Treatment | MPR= Days of medication possession from the prescriptions filled in the 180 days divided by (180 days plus + extra days of drug supply from the last prescription fill during the 180 days). MPR by each index drug including escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion is reported in this outcome measure. Index date was first prescription date of study drugs during intake period. | From index date (anytime between 01-Jan-2018 to 31-Dec-2019) up to 180 days of treatment (data collected and observed retrospectively) |
| Persistence During First 180 Days of Treatment | Persistence was defined as the average length of treatment on the index drugs (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion), allowing 14-day permissible gap. Index date was first prescription date of study drugs during intake period. | From index date (anytime between 01-Jan-2018 to 31-Dec-2019) up to 180 days of treatment (data collected and observed retrospectively) |
| Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date | Percentage of participants who discontinued the treatment in first 90 days from the index date is reported in this outcome measure. Index date was the first prescription date of study treatment during the intake period. | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
| Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) | Adherence was defined when MPR >= 75%. MPR = (Days of medication possession from the prescriptions filled in the 180 days) / (180 days + extra days of drug supply from the last prescription fill during the 180 days. Index date was the first prescription date of study drugs during the intake period. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase | Percentage of participants who received monotherapy, combination therapy and augmentation therapy during 90 days of treatment were assessed in this outcome measure. Acute treatment phase was during initial 90 days from the index date. | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
Inclusion Criteria
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
Exclusion Criteria
Patients meeting any of the following criteria will not be included in the study:
Not provided
Not provided
Not provided
Subjects who newly initiated antidepressant therapies between Jan 01, 2017 to Jun 30, 2018 in the National Health Insurance Service (NHIS) database
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer | Seoul | South Korea |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
A total of 370212 participants were included in the study.
Participants who initiated antidepressants between 01-Jan-2018 to 30-Jun-2019 in Health Insurance Review and Assessment (HIRA) service database were observed in this retrospective study. Index date was first prescription date of study drugs during intake period (01-Jan-2018 to 31-Dec-2019). Acute phase was initial 90 days of treatment period and maintenance phase was from 91 to 180 days of treatment. Participants were followed up until 31-Dec-2020.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Participants With Antidepressant Therapy | Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Full analysis set (FAS) included participants who had newly initiated antidepressant therapies between 01-Jan-2018, to 30-Jun-2019, in the HIRA database.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Participants With Antidepressant Therapy | Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Medication Possession Ratio (MPR) During First 180 Days of Treatment | MPR= Days of medication possession from the prescriptions filled in the 180 days divided by (180 days plus + extra days of drug supply from the last prescription fill during the 180 days). MPR by each index drug including escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion is reported in this outcome measure. Index date was first prescription date of study drugs during intake period. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Mean | Standard Deviation | Ratio | From index date (anytime between 01-Jan-2018 to 31-Dec-2019) up to 180 days of treatment (data collected and observed retrospectively) |
|
Data for non-serious adverse events and serious adverse events (SAEs) were not collected and evaluated during the study; hence timeframe is not applicable for non-SAEs and SAEs.
This study involved data that existed as structured data and in these data sources, individual participant data could not be retrieved or validated, and it was not possible to link (i.e., identify a potential association between) a particular product and medical event for any individual. The minimum criteria for reporting an adverse event (AE) (i.e., identifiable patient, identifiable reporter, a suspect product, and event) could not be met. Hence, safety data is not reported.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Participants With Antidepressant Therapy | Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquires@pfizer.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 10, 2021 | Oct 16, 2023 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Dec 20, 2022 | Oct 16, 2023 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000089983 | Escitalopram |
| D017374 | Paroxetine |
| D005473 | Fluoxetine |
| D000078785 | Mirtazapine |
| D000068736 | Duloxetine Hydrochloride |
| D020280 | Sertraline |
| D000069470 | Venlafaxine Hydrochloride |
| C050504 | tianeptine |
| D000078784 | Vortioxetine |
| D000069468 | Desvenlafaxine Succinate |
| D016642 | Bupropion |
| ID | Term |
|---|---|
| D011437 | Propylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D009570 | Nitriles |
| D001572 |
Not provided
Not provided
Not provided
Not provided
Not provided
| 9. Vortioxetine Cohort |
|
| 10. Desvenlafaxine Cohort |
|
| 11. Bupropion Cohort |
|
| Paroxetine |
| Drug |
Treatment for depression |
|
| Fluoxetine | Drug | Treatment for depression |
|
| Mirtazapine | Drug | Treatment for depression |
|
| Duloxetine | Drug | Treatment for depression |
|
| Sertraline | Drug | Treatment for depression |
|
| Venlafaxine | Drug | Treatment for depression |
|
| Tianeptine | Drug | Treatment for depression |
|
| Vortioxetine | Drug | Treatment for depression |
|
| Desvenlafaxine | Drug | Treatment for depression |
|
| Bupropion | Drug | Treatment for depression |
|
| From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 180 days of treatment (data collected and observed retrospectively) |
| Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase | Recurrence during the acute treatment phase was defined as either one of the following: 1) Inpatient episode with a diagnosis code. 2) Inpatient episodes via the department of psychiatry or emergency medicine. 3) Inpatient episode via nursing hospital. 4) Emergency room visit with a diagnosis code. 5) Suicide attempt. Acute phase considered as the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period. Diagnosis codes used for inclusion were: F06.3-Organic mood(affective) disorders, F32*- Depressive episode, F33*- Recurrent depressive disorder, F34.1- Neurotic depression, F38.1- Other recurrent mood(affective) disorders, F41.2- Mixed anxiety and depressive disorder. | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
| Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase | Recurrence was defined as either one of the following: 1) Inpatient episode with a diagnosis code. 2) Inpatient episodes via the department of psychiatry or emergency medicine. 3) Inpatient episode via nursing hospital. 4) Emergency room visit with a diagnosis code. 5) Suicide attempt; antidepressant prescription after 30 days of drug holiday. Acute phase considered as the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period. | From day 91 to day 180 from the index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively) |
| Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment | An AE was any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. Maintenance phase was during the second 90-day period (91 to 180 days) starting from the index date. Index date was the first prescription date of study treatment during the intake period. Index date was the first prescription date of study treatment during the intake period. | From 91 up to 180 days of treatment from index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively) |
| Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase | Percentage of prescriptions for commonly used antidepressants in acute treatment phase were assessed. Acute treatment phase was during the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period. | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
| Average Daily Dosage at Index Date | Index date was the first prescription date of study treatment during the intake period. | At index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively) |
| Average Daily Dosage During the Acute Treatment Phase | Acute treatment phase was during the first 90-day period starting from the index date. | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
| Drug Utilization Pattern of Participants During 90-180 Days of Treatment | The drug utilization pattern is presented according to the average treatment duration for each antidepressant during the maintenance treatment phases. | From 90 days to 180 days of treatment (data collected and observed retrospectively) |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
Participants who initiated antidepressant therapy (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion) between 01-Jan-2018 to 30-Jun-2019 in the HIRA database were included and observed. |
|
|
| Primary | Persistence During First 180 Days of Treatment | Persistence was defined as the average length of treatment on the index drugs (escitalopram, paroxetine, fluoxetine, mirtazapine, duloxetine, sertraline, venlafaxine, tianeptine, vortioxetine, desvenlafaxine and bupropion), allowing 14-day permissible gap. Index date was first prescription date of study drugs during intake period. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Mean | Standard Deviation | Days | From index date (anytime between 01-Jan-2018 to 31-Dec-2019) up to 180 days of treatment (data collected and observed retrospectively) |
|
|
|
| Primary | Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date | Percentage of participants who discontinued the treatment in first 90 days from the index date is reported in this outcome measure. Index date was the first prescription date of study treatment during the intake period. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Number | Percentage of participants | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
|
|
|
| Primary | Percentage of Participants Who Adhered to Treatment Measured by MPR (More Than or Equal to [>=] 75 Percent [%]) | Adherence was defined when MPR >= 75%. MPR = (Days of medication possession from the prescriptions filled in the 180 days) / (180 days + extra days of drug supply from the last prescription fill during the 180 days. Index date was the first prescription date of study drugs during the intake period. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Number | Percentage of participants | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 180 days of treatment (data collected and observed retrospectively) |
|
|
|
| Primary | Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase | Recurrence during the acute treatment phase was defined as either one of the following: 1) Inpatient episode with a diagnosis code. 2) Inpatient episodes via the department of psychiatry or emergency medicine. 3) Inpatient episode via nursing hospital. 4) Emergency room visit with a diagnosis code. 5) Suicide attempt. Acute phase considered as the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period. Diagnosis codes used for inclusion were: F06.3-Organic mood(affective) disorders, F32*- Depressive episode, F33*- Recurrent depressive disorder, F34.1- Neurotic depression, F38.1- Other recurrent mood(affective) disorders, F41.2- Mixed anxiety and depressive disorder. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Number | Percentage of participants | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
|
|
|
| Primary | Percentage of Participants Experiencing Recurrence After the Acute Treatment Phase | Recurrence was defined as either one of the following: 1) Inpatient episode with a diagnosis code. 2) Inpatient episodes via the department of psychiatry or emergency medicine. 3) Inpatient episode via nursing hospital. 4) Emergency room visit with a diagnosis code. 5) Suicide attempt; antidepressant prescription after 30 days of drug holiday. Acute phase considered as the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Number | Percentage of participants | From day 91 to day 180 from the index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively) |
|
|
|
| Primary | Percentage of Participants With Adverse Events (AE) Within Maintenance Phase of Treatment | An AE was any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. Maintenance phase was during the second 90-day period (91 to 180 days) starting from the index date. Index date was the first prescription date of study treatment during the intake period. Index date was the first prescription date of study treatment during the intake period. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Number | Percentage of Participants | From 91 up to 180 days of treatment from index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively) |
|
|
|
| Primary | Percentage of Prescriptions for Commonly Used Antidepressants in Acute Treatment Phase | Percentage of prescriptions for commonly used antidepressants in acute treatment phase were assessed. Acute treatment phase was during the first 90-day period starting from the index date. Index date was the first prescription date of study treatment during the intake period. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. | Posted | Number | Percentage of prescriptions | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) | Prescriptions for antidepressants | Prescriptions for antidepressants |
|
|
|
| Primary | Average Daily Dosage at Index Date | Index date was the first prescription date of study treatment during the intake period. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018, to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Mean | Standard Deviation | Milligrams per day | At index date (anytime between 01-Jan-2018 to 30-Jun-2019) (data collected and observed retrospectively) |
|
|
|
| Primary | Average Daily Dosage During the Acute Treatment Phase | Acute treatment phase was during the first 90-day period starting from the index date. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Overall Number of Participants Analyzed' signifies number of participants who were treated with monotherapy and 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Mean | Standard Deviation | Milligrams per day | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
|
|
|
| Other Pre-specified | Percentage of Participants on Monotherapy, Combination Therapy, Augmentation Therapy During Acute Treatment Phase | Percentage of participants who received monotherapy, combination therapy and augmentation therapy during 90 days of treatment were assessed in this outcome measure. Acute treatment phase was during initial 90 days from the index date. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows. One participant was evaluable for more than one row. | Posted | Number | Percentage of Participants | From the index date (anytime between 01-Jan-2018 to 30-Jun-2019) up to 90 days of treatment (data collected and observed retrospectively) |
|
|
|
| Other Pre-specified | Drug Utilization Pattern of Participants During 90-180 Days of Treatment | The drug utilization pattern is presented according to the average treatment duration for each antidepressant during the maintenance treatment phases. | FAS included participants who had newly initiated antidepressant therapies between 01-Jan-2018 to 30-Jun-2019, in the HIRA database. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. | Posted | Mean | Standard Deviation | Days | From 90 days to 180 days of treatment (data collected and observed retrospectively) |
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Benzofurans |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D003984 | Dibenzazepines |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |
| D015057 | 1-Naphthylamine |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D003511 | Cyclohexanols |
| D000441 | Hexanols |
| D005233 | Fatty Alcohols |
| D000438 | Alcohols |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D008055 | Lipids |
| D010879 | Piperazines |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D011427 | Propiophenones |
| D007659 | Ketones |
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|
| Title | Measurements |
|---|---|
|
| Sertraline |
|
| Duloxetine |
|
| Venlafaxine |
|
| Desvenlafaxine |
|
| Mirtazapine |
|
| Tianeptine |
|
| Vortioxetine |
|
| Bupropion |
|
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|
|
| Augmentation therapy: escitalopram |
|
|
| Monotherapy: Paroxetine |
|
|
| Combination: Paroxetine |
|
|
| Augmentation therapy: paroxetine |
|
|
| Monotherapy: Fluoxetine |
|
|
| Combination: Fluoxetine |
|
|
| Augmentation therapy: fluoxetine |
|
|
| Monotherapy: Sertraline |
|
|
| Combination: Sertraline |
|
|
| Augmentation therapy: sertraline |
|
|
| Monotherapy: Duloxetine |
|
|
| Combination: Duloxetine |
|
|
| Augmentation therapy: duloxetine |
|
|
| Monotherapy: Venlafaxine |
|
|
| Combination: Venlafaxine |
|
|
| Augmentation therapy: venlafaxine |
|
|
| Monotherapy: Desvenlafaxine |
|
|
| Combination: Desvenlafaxine |
|
|
| Augmentation therapy: desvenlafaxine |
|
|
| Monotherapy: Mirtazapine |
|
|
| Combination: Mirtazapine |
|
|
| Augmentation therapy: mirtazapine |
|
|
| Monotherapy: Tianeptine |
|
|
| Combination: Tianeptine |
|
|
| Augmentation therapy: tianeptine |
|
|
| Monotherapy: Vortioxetine |
|
|
| Combination: Vortioxetine |
|
|
| Augmentation therapy: vortioxetine |
|
|
| Monotherapy: Bupropion |
|
|
| Combination: Bupropion |
|
|
| Augmentation therapy: bupropion |
|
|
|
| Fluoxetine |
|
|
| Sertraline |
|
|
| Duloxetine |
|
|
| Venlafaxine |
|
|
| Desvenlafaxine |
|
|
| Mirtazapine |
|
|
| Tianeptine |
|
|
| Vortioxetine |
|
|
| Bupropion |
|
|